News

Nestmedic has signed a strategic distribution agreement with Synektik. According to the agreement, Synektik becomes the exclusive distributor of Pregnabit Pro devices and the Pregnabit Cloud telemedicine platform in Poland, the Czech Republic (as of 1 September) and Slovakia. The agreement was signed for three years with the possibility of extension. The Synektik Group is an integrator of innovative medical solutions especially for oncology, cardiology and neurology, which imports into Poland and popularises the latest technologies on the domestic market, including the Da Vinci robotic system, used for surgical procedures in the areas of gynaecology, urology and general surgery, among others. Synektik is also developing and commercialising health IT solutions. Observing the great potential in the development and increased importance of telemedicine in the medical market, Pregnabit Pro and the Pregnabit Cloud platform naturally fit into the company’s growth strategy. For Nestmedic, expanding its presence in international markets is a priority. The partnership with Synektik is an excellent example of the Company’s commitment to expansion and efforts to increase sales of our fetal wellbeing monitoring system. We are delighted to be working with such a reputable partner, whose commitment and professionalism will allow us to reach a wide range of patients in the region with the Pregnabit System, consisting of Pregnabit Pro devices and the Pregnabit Cloud platform. We believe that this collaboration will yield fruitful results and open new horizons of commercialisation.

We’re thrilled to see our partnerships thriving! Thanks to the fruitful collaboration with our distributor, AdiTech, expectant mothers in an Italian hospital will soon have comprehensive pregnancy care using Pregnabit Pro devices and the platform! 🇮🇹 This exciting development marks another step in our sales growth journey. Together with our partners, we’re making a positive impact on the lives of expectant mothers and their babies.

We are one step closer to achieving a crucial goal – obtaining FDA certification. In our unwavering commitment, we have reached a new milestone. We have successfully undergone a highly significant electromagnetic compatibility (EMC) compliance study, basic safety tests, and performance evaluations conducted by one of ASCA-accredited research laboratories (UL Solutions). The studies were conducted in accordance with rigorous medical device standards (ISO 60601-1, ISO 60601-1-11, ISO 60601-1-2, ISO 60601-2-37), fully confirming that the Pregnabit Pro devices and PregnaOne platform have received full compliance confirmation. This signifies that we fulfill the additional requirements necessary to obtain approval from the U.S. Food and Drug Administration (FDA) to introduce modern patient care methods through Nestmedic products for use by American doctors and, above all, their patients. Obtaining FDA certification will enable Nestmedic to commercialize its offerings in the American market. The value of telemedicine services in the United States is estimated to exceed $150 billion USD by 2030, indicating a strengthening trend in telemedicine. It’s worth noting that in 2022, North America held a 36% share in the global telemedicine market, corresponding to nearly $23 billion USD. Nestmedic remains committed to meeting all formal requirements aimed at initiating sales in the USA, thereby aligning with this growing trend. We continue to strive for providing access to innovative solutions for women’s health worldwide.